Investor Presentaiton
INOVIO DNA Medicine Value Proposition
NASDAQ:INO
•
•
Validated Technology Platform
.
•
•
Demonstrated Phase 2b clinical efficacy of lead asset VGX-3100
Validated safety data in >2,000 patients and >7,000 administrations with
CELLECTRA smart device, and consistent demonstration of high levels of
T cell and antibody immune responses
Well-protected with over 1,000 issued and pending patents
Over $210M in non-dilutive funding since 2009
Partnerships with major pharma and organizations:
CEPI BILL&MELINDA
GATES foundation
AstraZeneca
DARPA
DEPARTMENT
OF
DEFENSE
UNITED STATES
AMERICA
OF
Multiple catalysts in 2020
•
•
INO-5401 Phase 2 GBM OS18 data
VGX-3100 Phase 3 cervical precancer topline data readout
•
INO-4800 Phase 1 safety/immunogenicity publication/Conduct Phase 2/3
39
PICI
PARKER
INSTITUTE
FOR CANCER
IMMUNOTHERAPY
REGENERON
NIH
INOVIO
POWERING DNA MEDICINESView entire presentation